Broadfin Capital, LLC (CIK: 0001511901) is a financial institution headquartered at 237 Park Avenue, 9Th Floor, , New York, New York 10017. The firm regularly files Form 13F with the U.S. Securities and Exchange Commission (SEC), disclosing its equity holdings and investment positions.
As of the latest reporting period (2019-12-31), the institution manages a portfolio valued at $746.81 M, comprising 40 distinct securities. Over its filing history, it has submitted 32 Form 13F reports.
To view the institution’s full SEC filing history:
🔗 View All SEC Filings
Q4 2019 — Top-10 concentration: 50.1%. Quarterly turnover: 34.4%. ▲ 10 new, +10 added, −12 reduced, ×13 exited.
| Name | Shares | Market Value | Weight | Change | Activity |
|---|---|---|---|---|---|
|
Biodelivery Sciences Intl In
N/A
|
4.3 M | $27.18 M | 3.64% | ||
| 5.57 M | $23.52 M | 3.15% | ▲ 2,573,005 | Add 85.7% | |
| 52,462 | $22.5 M | 3.01% | ▼ 25,989 | Reduce -33.1% | |
| 409,338 | $22.28 M | 2.98% | ▼ 123,253 | Reduce -23.1% | |
| 1.03 M | $21.08 M | 2.82% | ▲ 784,500 | Add 315.1% | |
|
Quotient
N/A
|
1.99 M | $18.96 M | 2.54% | ▲ 1,380,754 | Add 225.1% |
|
Eiger Biopharmaceuticals
N/A
|
1.24 M | $18.42 M | 2.47% | ▼ 131,009 | Reduce -9.6% |
| 462,118 | $16.25 M | 2.18% | ▲ 462,118 | New Buy | |
|
Intersect Ent
N/A
|
631,023 | $15.71 M | 2.10% | ▼ 148,111 | Reduce -19.0% |
|
Progenics Pharmaceuticals In
N/A
|
3.06 M | $15.58 M | 2.09% | ▲ 1,476,998 | Add 93.3% |